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Abstract
Background: Alzheimer’s Disease (AD) is the most common neurodegenerative disease and the leading cause of dementia
among senile subjects. It has been proposed that AD can be caused by defects in mitochondrial oxidative phosphorylation.
Given the fundamental contribution of the mitochondrial genome (mtDNA) for the respiratory chain, there have been a
number of studies investigating the association between mtDNA inherited variants and multifactorial diseases, however no
general consensus has been reached yet on the correlation between mtDNA haplogroups and AD.
Methodology/Principal Findings: We applied for the first time a high resolution analysis (sequencing of displacement loop
and restriction analysis of specific markers in the coding region of mtDNA) to investigate the possible association between
mtDNA-inherited sequence variation and AD in 936 AD patients and 776 cognitively assessed normal controls from central
and northern Italy. Among over 40 mtDNA sub-haplogroups analysed, we found that sub-haplogroup H5 is a risk factor for
AD (OR=1.85, 95% CI:1.04–3.23) in particular for females (OR=2.19, 95% CI:1.06–4.51) and independently from the APOE
genotype. Multivariate logistic regression revealed an interaction between H5 and age. When the whole sample is
considered, the H5a subgroup of molecules, harboring the 4336 transition in the tRNA
Gln gene, already associated to AD in
early studies, was about threefold more represented in AD patients than in controls (2.0% vs 0.8%; p=0.031), and it might
account for the increased frequency of H5 in AD patients (4.2% vs 2.3%). The complete re-sequencing of the 56 mtDNAs
belonging to H5 revealed that AD patients showed a trend towards a higher number (p=0.052) of sporadic mutations in
tRNA and rRNA genes when compared with controls.
Conclusions: Our results indicate that high resolution analysis of inherited mtDNA sequence variation can help in
identifying both ancient polymorphisms defining sub-haplogroups and the accumulation of sporadic mutations associated
with complex traits such as AD.
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Introduction
Alzheimer’s Disease (AD) is the most common neurodegenerative
disease and the leading cause of dementia among senile subjects. Few
AD cases are early onset and familial, with autosomal dominant
inheritance, while the majority of cases are late-onset (over 60 years
old) and sporadic [1]. Sporadic AD (SAD) has a complex aetiology
due to environmental and genetic factors which taken alone are not
sufficient to cause the disease. Presently the major genetic risk factor
in SAD is recognized in the allele e4 of apolipoprotein E (ApoE4).
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are still unknown and there is likely a complex interaction between
genetic and environmental factors that eventually results in the
pathology [2].
It has been proposed that SAD can be caused by defects in
mitochondrial oxidative phosphorylation (OXPHOS) [3]. Struc-
turally abnormal mitochondria have been observed in AD brains
[4], and deficiencies in mitochondrial OXPHOS enzymes, such as
cytocrome c oxidase, have been repeatedly reported in the brains
and other tissues of AD patients [5,6]. Mitochondria are deeply
involved in various cellular processes such as ATP synthesis, heat
production, reactive oxygen species (ROS) generation through
oxidative phosphorylation, but also calcium signalling and
apoptosis [7,8]. Defects in OXPHOS inhibit ATP production,
but also increase mitochondrial ROS production, which, in turn,
can damage the mitochondrial genome (mtDNA). Thus, this
hypothesis on AD pathogenesis claims that mitochondrial
impairment may result from accumulated mtDNA damage that
accompanies normal aging, amplified by disease-specific factors
[9,3]. Although there were reports of somatic mutations
specifically at sites of known mtDNA regulatory elements, the
available data from hybrid studies and post-mortem brain
examinations did not provide conclusive proof that somatic
mtDNA mutations can play a major or dominant role in AD
aetiology [10,11].
Human mtDNA codes for the 12S and 16S mitochondrial
rRNAs, 22 tRNAs, and 13 polypeptides; these polypeptides are
essential subunits of mitochondrial OXPHOS enzyme complexes,
which generate the principal source of intracellular energy, ATP
[12,8]. It is inherited almost exclusively through the maternal
lineage, does not recombine and is highly polymorphic. Mito-
chondrial genomes can be affiliated within haplogroups and sub-
haplogroups on the basis of their specific sequence motifs,
reflecting mutation events accumulated over time along diverging
maternal lineages. These haplogroups tend to show a continental
or regional localization, and a very large number of European,
African, and Asian/Native American-specific haplogroups have
been identified so far [13,14].
Given the fundamental contribution of the mitochondrial
genome for the respiratory chain, there have been a number of
studies investigating the association between mtDNA lineages,
aging and multifactorial diseases. It has been hypothesised that
some mtDNA haplogroups are not neutral and have been selected
through adaptation to climate and nutritional conditions
[15,8,16]. Moreover, there are many reports on the association
between mtDNA haplogroups and longevity [17–19], Leber
hereditary optic neuropathy [20], as well as complex diseases like
diabetes [21], ischaemic disease [22] and neurodegenerative
diseases like Parkinson’s Disease [23] and AD.
As for AD, contrasting data have been published. Some studies
suggested that the transition at np 4336 of the mitochondrial
tRNA glutamine gene is a risk factor for AD [24–26]. This
mutation characterizes a European sub-branch of haplogroup H
[13], which was termed H5a in more recent years [27,28]. Later it
has been reported that haplogroup T is under-represented
whereas haplogroup J is over-represented in AD patients [29].
Haplogroup U has been reported to be under-represented in
females and over-represented in male AD patients of European
ancestry [30], while recently, it has been found that HV cluster is
significantly associated with the risk of AD regardless of the gender
and the APOE4 status [31]. On the other side, it is to note that
several studies did not find any association between mtDNA
haplogroups and AD by studying different European populations
[32–34,11,35]. On the whole, no general consensus has been
reached on the correlation between mtDNA haplogroups and AD
[36].
Since AD is a common neurodegenerative disorder, affecting
globally about 3% of people older than 60 years in the world [37],
even a small risk associated with mtDNA haplotype could have
major causative implications at a population level. It is therefore
critically important to determine the role of mtDNA polymor-
phisms in AD by studying large cohorts of subjects at a level of
molecular and phylogenetic resolution as fine as possible. Our
study is then aimed to investigate the possible association of
mtDNA at the sub-haplogroup level in a population of 936 AD
patients and 776 controls from central-northern Italy, in order to
clarify whether specific sub-haplogroup polymorphic sites are
involved in AD, and to assess the possibility that associations
detectable only at the sub-haplogroup resolution level might
account for the discrepancies present in the literature regarding
AD and European mtDNA inherited variability.
Results
In our total sample of 1712 Italian subjects (936 AD patients
and 776 controls) there is a higher proportion of female (72.9%)
and APOE4+ (43.5%) subjects among AD patients relative to
controls (60.6% and 13.1%, respectively). A separate comparison
of genders further confirmed that APOE4 carriers were signifi-
cantly different between AD patients and controls (Table 1).
The hierarchical survey of diagnostic markers in the coding
region allowed the classification of mtDNAs from patients and
controls into more than 40 haplogroups/sub-haplogroups (Table
S1). Most of these are typical of modern European populations,
but a few East Asian (M) [38] and sub-Saharan African (L1b, L2a,
L2c, L3d, L3e) [16,39] mtDNAs were also detected. This latter
finding is not unexpected, since low frequencies of African and
East Asian haplogroups are not uncommon in populations of
southern Europe. We then grouped, using a phylogenetic rationale
whenever possible, all sub-haplogroups with frequencies lower
than 1.5%, thus allowing a reduction of the overall number of
categories from over 39 to 19.
No difference was found between AD patients and controls in
the distribution of mtDNA groupings (Table 2). We further
proceeded by comparing the 19 sub-haplogroup frequencies in
Table 1. Characteristics of the study participants.
AD patients
(N=936)
Controls
(N=776) p-value
Age (years) (mean6SD) 76.567.6 73.767.2
Gender Female 72.9% 60.6% ,0.0001
Male 27.1% 39.4%
APOE4 status APOE4+ 43.5% 13.1% ,0.0001
APOE4- 56.5% 86.9%
Female (N=682) (N=470)
Age (years) (mean6SD) 77.167.7 73.867.2
APOE4 status APOE4+ 43.4% 11.1% ,0.0001
APOE4- 56.6% 88.9%
Male (N=254) (N=306)
Age (years) (mean6SD) 75.167.2 73.467.1
APOE4 status APOE4+ 43.7% 16.3% ,0.0001
APOE4- 56.3% 83.7%
doi:10.1371/journal.pone.0012037.t001
mtDNA Subhaplogroup H5 in AD
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comparison adjustments (p-value cut-off=0.003); again no
statistical difference was observed.
Also when frequencies were compared separately for gender, we
found no difference between AD patients and controls for the
mtDNA, and overall no significant differences among the sub-
haplogroup frequencies (Tables S2 and S3).
We then performed a univariate logistic regression analysis with
the mtDNA variable to identify the potential sub-haplogroup
associated with AD. Using as reference the haplogroup H, the only
sub-haplogroup that resulted statistically associated with AD was
H5 (OR=1.89, 95%CI =1.03–3.42). Hence we created a
dichotomous variable (H5 versus all other sub-haplogroups) and
performed again the logistic regression analysis including sex, age
and APOE4.Overall sub-haplogroup H5 has a slightly higher AD
risk (OR=2.19, 95%CI =1.06–4.51) in the female group than in
the total sample (OR=1.83, 95%CI =1.04–3.23). As expected, in
our population APOE4 carriers have a higher AD risk than non-
APOE4 carriers (OR=5.08, 95%CI =3.98–6.50) and, among
them, women have a higher risk than men (OR=6.16, 95%CI
=4.45–8.53, OR=3.97, 95%CI =2.69–5.88, respectively).
Subsequently, mitochondrial sub-haplogroup H5 and the major
acknowledged risk factors for AD (gender, age, APOE4) were
compared in multivariate regression analysis. As shown in
Table 3, gender (female), APOE4 allele, age and sub-haplogroup
H5 are confirmed to be risk factor for AD. Moreover sub-
haplogroup H5 interacts with age in modifying AD risk. Subjects
younger than 75 years (corresponding to the median age in the
total sample) and carrying sub-haplogroup H5 harbor a four-fold
increased AD risk than subjects belonging to other sub-
haplogroups, while among subjects who do not carry sub-
haplogroup H5, those older than 75 years have a three-fold
increased risk than younger subjects.
We then performed the multivariate logistic regression by gender.
In the female group APOE4 allele, age and sub-haplogroup H5 are
confirmed to be risk factor for AD, and the APOE4 allele interacts
with age in modulating AD risk. In female subjects aged 76 years
(corresponding to the median age in the female sample) or younger,
those carrying the APOE4 allele have a ten-fold increased AD risk
than non APOE4 carriers, while within subjects older than 76 years,
thosecarryingtheAPOE4allelehaveanearlyfour-foldincreasedAD
risk than non-APOE4 carriers. Among female non-APOE4 carriers,
those older than 76 years have a four-fold increased AD risk than
younger subjects (Table 4). In the male group only APOE4 allele
(OR=3.87, 95%CI =2.60–5.77) and age .74 years (OR=2.15,
95%CI =1.51–3.07)are confirmed to berisk factorsfor AD (data not
shown).
To determine whether the increased risk associated with sub-
haplogroup H5 could be attributed to specific mutations or
mutational motifs, the complete sequence of virtually all H5
mtDNAs (56 out of 57; 38 AD patients and 18 controls) in our
collection was determined and the phylogenetic distribution
among the samples was analyzed. The results of the phylogenetic
distribution and of the sequence analysis are summarized in
Table 5 and Figure 1. A total of 159 mutated positions relative
to the reference sequence [40] were detected and analyzed in the
network, including 104 nucleotide changes in the coding regions:
the count of each kind of mutation is important in order to
understand the mutational spectrum of the molecule and identify
Table 2. Frequencies of mtDNA sub-haplogroups in AD
patients and controls from Italy.
Sub-
haplogroupa AD patients Controls
(N=936) (N=776)
N% S E
b N% S E
b
H* 182 19,4 0,0129 156 20,1 0,0144
H1 115 12,3 0,0107 97 12,5 0,0119
H3 28 3,0 0,0056 18 2,3 0,0054
H5
c 39 4,2 0,0065 18 2,3 0,0054
H6 33 3,5 0,0060 21 2,7 0,0058
J1 64 6,8 0,0082 49 6,3 0,0087
J2 14 1,5 0,0040 13 1,7 0,0046
R0 46 4,9 0,0071 46 5,9 0,0085
T1 21 2,2 0,0048 17 2,2 0,0053
T2 84 9,0 0,0093 70 9,0 0,0103
U* 38 4,1 0,0065 32 4,1 0,0071
K 67 7,2 0,0084 68 8,8 0,0102
U4 23 2,5 0,0051 16 2,1 0,0051
U5a 46 4,9 0,0071 38 4,9 0,0077
U5b 18 1,9 0,0045 22 2,8 0,0060
V 31 3,3 0,0058 29 3,7 0,0068
W 20 2,1 0,0047 16 2,1 0,0051
X 26 2,8 0,0054 15 1,9 0,0049
Other 41 4,4 0,0067 35 4,5 0,0074
aSub-haplogroups with frequencies lower than 1.5% were grouped. Thus R0
includes R0a, R1, HV*, HV0*, HV0a, HV1 and HV2; H* includes all mtDNAs
belonging to haplogroup H, except those further classified (H1, H3, H5 and
H6); the same rationale has been used for U*; whereas ‘‘Other’’ contains the
heterogeneous haplogroups I, L1b, L2a, L2c, L3d, L3e, M, N and N1.
bStandard Error.
cOnly for H5 there is a difference between AD patients and controls with a x
2 p-
value (not adjusted for multiple comparisons) of 0.034.
doi:10.1371/journal.pone.0012037.t002
Table 3. Wald x
2 statistic (p-value), Odds ratio and 95%
Confidence Intervals for factors associated with Alzheimer’s
disease in the entire sample.
AD patients (N=936) vs Controls
(N=776)
a
p-value OR 95%C.I.
Gender (Female) ,.0001 1.72 (1.37–2.16)
APOE4 status (APOE4+) ,.0001 5.54 (4.28–7.16)
AGE (years)
b Haplogroup
#75 Other 1.00
H5 0.0019 4.02 (1.67–9.66)
.75 Other 1.00
H5 0.5326 0.77 (0.33–1.77)
Haplogroup AGE (years)
b
Other #75 1.00
.75 ,.0001 3.12 (2.51–3.87)
H5 #75 1.00
.75 0.3918 0.59 (0.18–1.96)
aVariables included in the model are age, gender, APOE4 and mtDNA
haplogroup.
bCorresponds to median value.
doi:10.1371/journal.pone.0012037.t003
mtDNA Subhaplogroup H5 in AD
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in italics in Table 5) were not previously reported in either
MITOMAP (www.mitomap.org) or mtDB (www.genpat.uu.se/
mtDB) and each mutation was observed only in a single H5
mtDNA.
The topology of our mtDNA network matches published
European trees in most respects [41].The network data set
included 38 AD cases and 18 healthy controls, belonging to H5. A
reduced-median network was constructed based on the sequence
variations in the entire mtDNA molecules and by placing the
rCRS as reference (Figure 1).
The H5 network turned out to be star-like and constituted by a
number of sub-clusters. The major dichotomy is due to the
presence/absence of the 4336 mutation. The presence of this
mutation characterizes H5a (N=15) the cluster over represented
in AD patients (1.1% in patients vs. 0.6% in controls). Moreover,
entire mitochondrial sequence data show that H5a can be further
subdivided; in particular there is one sub-branch termed H5a1
and defined by the mutation 15833 which encompasses many of
mtDNAs within H5a (9 out of 15).
Twenty-nine of the mutations (in bold) listed in Table 5 result
in amino acid changes, but excluding the mutations 8860 and
15326 (rCRS private mutations), none was particularly common.
The highest frequencies were indeed reached by the mutations
5319 and 8563, each observed in one AD patient (2.6%) and two
controls (11.1%).
Among all mutations observed in the 56 H5 mtDNAs, the
mutated position at 15833, defining the H5a1 subgroup, was
observed in the 21.1% of the H5 AD patients and in the 5.5% of
controls, when compared with the entire sample this difference
was statistical significant (0.9% vs 0.1%; p=0.039). The nucleotide
change at np 4336 in the tRNA glutamine gene, already associated
to AD in previous studies [24,25], was observed in 50.0% of the
H5 AD patients and 33.3% of the controls. When the whole
sample is considered, the H5a subgroup of molecules, harboring
the 4336 transition, was about threefold more represented in AD
patients than in controls (2.0% vs 0.8%; p=0.031), and it might
account for the H5 frequency increase in AD patients (4.2% vs
2.3%).
We did not find any statistical significant result when comparing
the number of mutations along the mtDNA molecule by mtDNA
regions (Table 6). Subsequently, we searched for groups of
singleton mutations falling in specific mtDNA regions that may
increase the susceptibility to AD. In particular we focused on
singleton mutations falling in tRNA and rRNA genes, considering
that previous studies have shown that mutations in these genes,
including the transition at np 4336 (tRNA
Gln) and the G3196A
mutation (16S rRNA), may be associated with AD [24,42]. We
found that ten sporadic mutations (single occurrences) were
present in the tRNA plus rRNA genes from AD mtDNA
sequences, while only two sporadic mutations were found in the
same genes from controls. We verified the significance of this
finding by comparing the number of the tRNA+rRNA mutations
with the number of mutations falling in the remaining of coding
region (43 in AD patients and 37 in controls). The x
2 test, under
the hypothesis of a homogeneous distribution of mutations showed
a tenuous significance (p=0.05).
Discussion
Although there is large amount of evidence about the role of
mitochondria in the pathogenesis of AD, a definitive conclusion
regarding the association of mtDNA haplogroup with AD has not
been reached yet [36]. To date several studies reported lack of
association between mtDNA haplogroups and AD [32–34,11,35],
while others found positive associations with specific haplogroups
as well as specific haplogroup clusters analyzing different
Caucasian populations [24,29–31,43].
To our knowledge, this is the first case-control study
investigating, at the sub-haplogroup level, the association of
mtDNA with Alzheimer’s Disease. We analyzed a large cohort of
AD patients (N=936) and controls (N=776) comparable for age
and ethnicity from the central-northern regions of Italy, where the
controls were directly assessed for their cognitive status. We found
that sub-haplogroup H5 appears to be associated with a higher risk
of AD in both the total sample and the female group. This result
was in keeping with a recent study on the Polish population which
revealed that the super-haplogroup HV and haplogroup H are
associated with a higher risk of AD [31].
Studies of both survival after sepsis [44] and sperm motility [45]
have shown significant associations with mtDNA haplogroups,
leading to the proposal that mitochondria bearing haplogroup H
mtDNAs, and particularly haplogroups H3, H4, H5 and H6 [46] are
associated with a more tightly coupled oxidative phosphorylation,
and consequently they should lead to an increased production of
ROS thanthose withhaplogroupT. Accordingly, itwas hypothesized
that subjects with haplogroup H could be more prone to oxidative
stress than those with other haplogroups [8], and consequently more
susceptible to neurodegenerative diseases, in which oxidative stress
plays a major role. This hypothesis would account for the higher AD
risk we observed for H5 subjects.
We also found that sub-haplogroup H5 interacts with age in
modifying AD risk. H5 subjects younger than 75 years old have a
higher AD risk than non-H5 subjects, while in those older than 75
years no increased risk is observed. Age is a strong risk factor for
AD [37] and this interaction suggests that age 75, corresponding to
the median age in our sample, could be considered as a threshold,
under which risk factors such as sub-haplogroup H5 and APOE,
could independently exert their major effect on the development of
the disease, while over this age value other risk factors, such as
aging itself, would largely prevail.
Table 4. Wald x
2 statistic (p-value), Odds ratio and 95%
Confidence Intervals for factors associated with Alzheimer’s
disease in females.
AD patients (N=682) vs Controls
(N=470)
a
p-value OR 95%C.I.
mtDNA haplogroup (H5) 0.0327 2.38 (1.07–5.27)
AGE (years)
b APOE4 status
#76 APOE4- 1.00
APOE4+ ,.0001 9.56 (6.13–14.89)
.76 APOE4- 1.00
APOE4+ ,.0001 3.70 (2.26–6.08)
APOE4 status AGE (years)
b
APOE4- #76 1.00
.76 ,.0001 3.90 (2.91–5.24)
APOE4+ #76 1.00
.76 0.1744 1.51 (0.83–2.74)
aVariables included in the model are age, gender, APOE4 and mtDNA
haplogroup.
bCorresponds to median value.
doi:10.1371/journal.pone.0012037.t004
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haplogroup H5.
Nucleotide
Position
a Locus
Nucleotide
Change
Aminoacid
Change
b
AD Patients:
N=38 (%)
Controls
N=18 (%)
73 D-loop (HVSII) A.G non coding 2 (5,3) 0 (0)
146 D-loop (HVSII) T.C non coding 3 (7,9) 1 (5,5)
150 D-loop (HVSII) C.T non coding 1 (2,6) 0 (0)
151 D-loop (HVSII) C.T non coding 0 (0) 1 (5,5)
152 D-loop (HVSII) T.C non coding 7 (18,4) 5 (27,78)
189 D-loop (HVSII) A.G non coding 1 (2,6) 0 (0)
195 D-loop (HVSII) T.C non coding 1 (2,6) 0 (0)
195A D-loop (HVSII) T.A non coding 1 (2,6) 0 (0)
199 D-loop (HVSII) T.C non coding 0 (0) 1 (5,5)
204 D-loop (HVSII) T.C non coding 1 (2,6) 0 (0)
207 D-loop (HVSII) G.A non coding 5 (13,2) 4 (22,2)
252 D-loop (HVSII) T.C non coding 1 (2,6) 0 (0)
259 D-loop (HVSII) A.G non coding 0 (0) 1 (5,5)
263 D-loop (HVSII) A.G non coding 38 (100) 18 (100)
309+C D-loop (HVSII) ins non coding 7 (18,4) 7 (38,9)
309+CC D-loop (HVSII) ins non coding 5 (13,2) 1 (5,5)
315+C D-loop (HVSII) ins non coding 38 (100) 18 (100)
316 D-loop (HVSII) G.A non coding 1 (2,6) 0 (0)
334 D-loop (HVSII) T.C non coding 1 (2,6) 0 (0)
365 D-loop (HVSII) A.G non coding 1 (2,6) 0 (0)
373 D-loop A.G non coding 1 (2,6) 1 (5,5)
385 D-loop A.G non coding 1 (2,6) 0 (0)
456 D-loop (HVSIII) C.T non coding 37 (97,4) 18 (100)
456+T D-loop (HVSIII) ins non coding 1 (2,6) 0 (0)
460 D-loop (HVSIII) T.C non coding 0 (0) 1 (5,5)
489 D-loop (HVSIII) T.C non coding 1 (2,6) 0 (0)
513 D-loop (HVSIII) G.A non coding 2 (5,3) 1 (5,5)
523_524 delCA D-loop (HVSIII) del non coding 8 (21,1) 3 (16,7)
523_524+CA D-loop (HVSIII) ins non coding 2 (5,3) 0 (0)
593 tRNA phenylalanine T.C - 2 (5,3) 0 (0)
721 rRNA 12S T.C - 1 (2,6) 0 (0)
750 rRNA 12S A.G - 38 (100) 18 (100)
769 rRNA 12S G.A - 1 (2,6) 0 (0)
801 rRNA 12S A.G - 1 (2,6) 0 (0)
1120 rRNA 12S C.T - 1 (2,6) 0 (0)
1438 rRNA 12S A.G - 38 (100) 18 (100)
3368 NADH dehydrogenase subunit 1 T.CM e t N P . Thr P 1 (2,6) 0 (0)
3744 NADH dehydrogenase subunit 1 A.G synonymous 1 (2,6) 0 (0)
3753 NADH dehydrogenase subunit 1 T.C synonymous 2 (5,3) 0 (0)
3992 NADH dehydrogenase subunit 1 C.TT h r P . Met NP 0 (0) 1 (5,5)
4024 NADH dehydrogenase subunit 1 A.GT h r P . Ala NP 0 (0) 1 (5,5)
4336 tRNA glutamine T.C - 19 (50) 6 (33,3)
4659 NADH dehydrogenase subunit 2 G.AA l a N P . Thr P 1 (2,6) 0 (0)
4769 NADH dehydrogenase subunit 2 A.G synonymous 38 (100) 18 (100)
4820 NADH dehydrogenase subunit 2 G.A synonymous 0 (0) 1 (5,5)
4832 NADH dehydrogenase subunit 2 C.T synonymous 1 (2,6) 0 (0)
5004 NADH dehydrogenase subunit 2 T.C synonymous 0 (0) 1 (5,5)
5082 NADH dehydrogenase subunit 2 T.C synonymous 1 (2,6) 0 (0)
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5268 NADH dehydrogenase subunit 2 A.G Ile NP . Val NP 0 (0) 1 (5,5)
5302 NADH dehydrogenase subunit 2 T.C Ile NP . Thr P 0 (0) 1 (5,5)
5319 NADH dehydrogenase subunit 2 A.GT h r P . Ala NP 1 (2,6) 2 (11,1)
5471 NADH dehydrogenase subunit 2 G.A synonymous 2 (5,3) 0 (0)
5821 tRNA cysteine G.A - 1 (2,6) 0 (0)
5839 tRNA tyrosine C.T - 1 (2,6) 0 (0)
5899+C - ins - 0 (0) 1 (5,5)
6425 Cytochrome c oxidase subunit 1 T.C synonymous 2 (5,3) 2 (11,1)
7364 Cytochrome c oxidase subunit 1 A.G synonymous 1 (2,6) 0 (0)
7444 Cytochrome c oxidase subunit 1 G.A STOP . Lys 0 (0) 1 (5,5)
7474 tRNA serine A.G - 1 (2,6) 0 (0)
7645 Cytochrome c oxidase subunit 2 C.T synonymous 1 (2,6) 0 (0)
7853 Cytochrome c oxidase subinit 2 G.AV a l N P . Ile NP 0 (0) 1 (5,5)
7861 Cytochrome oxidase subunit 2 T.C synonymous 1 (2,6) 0 (0)
7961 Cytochrome c oxidase subunit 2 T.C synonymous 0 (0) 1 (5,5)
7999 Cytochrome oxidase subunit 2 T.C synonymous 1 (2,6) 0 (0)
8011 Cytochrome c oxidase subunit 2 A.G synonymous 1 (2,6) 0 (0)
8053 Cytochrome c oxidase subinit 2 A.G synonymous 0 (0) 1 (5,5)
8188 Cytochrome c oxidase subunit 2 A.G synonymous 1 (2,6) 0 (0)
8277 - T.C - 1 (2,6) 0 (0)
8343 tRNA lysine A.G - 1 (2,6) 0 (0)
8348 tRNA lysine A.G - 2 (5,3) 0 (0)
8434G ATP synthase F0 subunit 8 C.G Ile NP . Met NP 1 (2,6) 0 (0)
8473 ATP synthase F0 subunit 8 T.C synonymous 0 (0) 1 (5,5)
8557 ATP synthase F0 subunit 6 G.AA l a N P . Thr P 0 (0) 1 (5,5)
8563 ATP synthase F0 subunit 6 A.GT h r P . Ala NP 1 (2,6) 2 (11,1)
8593 ATP synthase F0 subunit 6 A.G Ile NP .Val NP 0 (0) 1 (5,5)
8803T ATP synthase F0 subunit 6 A.TT h r P . Ser P 1 (2,6) 0 (0)
8857 ATP synthase F0 subunit 6 G.AG l y N P . Ser P 1 (2,6) 0 (0)
8860 ATP synthase F0 subunit 6 A.GT h r P . Ala NP 38 (100) 18 (100)
9010 ATP synthase F0 subunit 6 G.AA l a N P . Thr P 0 (0) 1 (5,5)
9123 ATP synthase F0 subunit 6 G.A synonymous 0 (0) 1 (5,5)
9515 Cytochrome c oxidase subunit 3 C.T synonymous 1 (2,6) 0 (0)
10172 NADH dehydrogenase subunit 3 G.A synonymous 2 (5,3) 0 (0)
10211 NADH dehydrogenase subunit 3 C.T synonymous 0 (0) 1 (5,5)
10217 NADH dehydrogenase subunit 3 A.G synonymous 1 (2,6) 0 (0)
10256 NADH dehydrogenase subunit 3 T.C synonymous 1 (2,6) 0 (0)
10275 NADH dehydrogenase subunit 3 T.C synonymous 1 (2,6) 0 (0)
10289 NADH dehydrogenase subunit 3 A.G synonymous 0 (0) 1 (5,5)
10310 NADH dehydrogenase subunit 3 G.A synonymous 1 (2,6) 0 (0)
10410 tRNA arginine T.C - 5 (13,2) 4 (22,2)
10454 tRNA arginine T.C - 0 (0) 1 (5,5)
10646 NADH dehydrogenase subunit 4L G.A synonymous 1 (2,6) 0 (0)
10664A NADH dehydrogenase subunit 4L C.A synonymous 0 (0) 1 (5,5)
10907 NADH dehydrogenase subunit 4 T.C Phe NP . Leu NP 1 (2,6) 0 (0)
10915 NADH dehydrogenase subunit 4 T.C synonymous 2 (5,3) 0 (0)
11084 NADH dehydrogenase subunit 4 A.GT h r P . Ala NP 1 (2,6) 0 (0)
11087 NADH dehydrogenase subunit 4 T.C Phe NP . Leu NP 0 (0) 1 (5,5)
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11089 NADH dehydrogenase subunit 4 C.T synonymous 0 (0) 1 (5,5)
11147 NADH dehydrogenase subunit 4 T.C synonymous 0 (0) 1 (5,5)
11329 NADH dehydrogenase subunit 4 A.G synonymous 1 (2,6) 0 (0)
11686 NADH dehydrogenase subunit 4 C.T synonymous 0 (0) 1 (5,5)
11914 NADH dehydrogenase subunit 4 G.A synonymous 1 (2,6) 0 (0)
11959 NADH dehydrogenase subunit 4 A.G synonymous 0 (0) 1 (5,5)
11965 NADH dehydrogenase subunit 4 C.T synonymous 1 (2,6) 0 (0)
12088 NADH dehydrogenase subunit 4 C.T synonymous 0 (0) 1 (5,5)
12246 tRNA serine2 C.T - 0 (0) 1 (5,5)
12471 NADH dehydrogenase subunit 5 T.C synonymous 1 (2,6) 0 (0)
12501 NADH dehydrogenase subunit 5 G.A synonymous 1 (2,6) 0 (0)
12723 NADH dehydrogenase subunit 5 A.G synonymous 1 (2,6) 0 (0)
12771 NADH dehydrogenase subunit 5 G.A synonymous 1 (2,6) 0 (0)
12864 NADH dehydrogenase subunit 5 T.C synonymous 1 (2,6) 0 (0)
13194 NADH dehydrogenase subunit 5 G.A synonymous 2 (5,3) 0 (0)
13434 NADH dehydrogenase subunit 5 A.G synonymous 1 (2,6) 1 (5,5)
13473 NADH dehydrogenase subunit 5 A.G synonymous 1 (2,6) 0 (0)
13651 NADH dehydrogenase subunit 5 A.GT h r P . Ala NP 1 (2,6) 0 (0)
13708 NADH dehydrogenase subunit 5 G.AA l a N P . Thr P 1 (2,6) 0 (0)
13725 NADH dehydrogenase subunit 5 C.T synonymous 5 (13,2) 4 (22,2)
14200 NADH dehydrogenase subunit 6 T.C synonymous 1 (2,6) 0 (0)
14311G NADH dehydrogenase subunit 6 T.G Tyr NP . Asp A 1 (2,6) 0 (0)
14319 NADH dehydrogenase subunit 6 T.C Asn P . Asp A 1 (2,6) 0 (0)
14365 NADH dehydrogenase subunit 6 C.T synonymous 0 (0) 1 (5,5)
14582 NADH dehydrogenase subunit 6 A.GV a l N P . Ala NP 0 (0) 1 (5,5)
14668 NADH dehydrogenase subunit 6 C.T synonymous 1 (2,6) 0 (0)
14831 Cytochrome b G.AA l a N P . Thr P 1 (2,6) 0 (0)
14893 Cytochrome b A.G synonymous 0 (0) 1 (5,5)
15001 Cytochrome b T.C synonymous 0 (0) 1 (5,5)
15139 Cytochrome b T.C synonymous 2 (5,3) 0 (0)
15172 Cytochrome b G.A synonymous 1 (2,6) 0 (0)
15175 Cytochrome b C.T synonymous 0 (0) 1 (5,5)
15213 Cytochrome b T.C Ile NP . Thr P 0 (0) 1 (5,5)
15326 Cytochrome b A.G Tyr NP . Asp A 38 (100) 18 (100)
15511 Cytochrome b T.C synonymous 0 (0) 1 (5,5)
15833 Cytochrome b C.T synonymous 8 (21,1) 1 (5,5)
15884 Cytochrome b G.AA l a N P .Thr P 2 (5,3) 1 (5,5)
15889 tRNA threonine T.C - 1 (2,6) 0 (0)
15910 tRNA threonine C.T - 1 (2,6) 0 (0)
15930 D-loop G.A non coding 2 (5,3) 1 (5,5)
15940 D-loop T.C non coding 1 (2,6) 0 (0)
16092 D-loop (HVSI) T.C non coding 1 (2,6) 0 (0)
16093 D-loop (HVSI) T.C non coding 2 (5,3) 0 (0)
16124 D-loop (HVSI) T.C non coding 0 (0) 1 (5,5)
16129 D-loop (HVSI) G.A non coding 1 (2,6) 0 (0)
16145 D-loop (HVSI) G.A non coding 1 (2,6) 1 (5,5)
16148 D-loop (HVSI) C.T non coding 1 (2,6) 0 (0)
16201 D-loop (HVSI) C.T non coding 1 (2,6) 0 (0)
Table 5. Cont.
mtDNA Subhaplogroup H5 in AD
PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12037The presence of mtDNA sub-haplogroup H5 confers a greater
risk of AD to women than to the total sample of AD patients
considered. In our sample the proportion of AD females was
higher than in the female control group, however we can exclude
that the association is merely due to a gender imbalance because
the frequencies of all haplogroups in AD females were comparable
to the female controls (and also to male controls), these latter being
similar to the northern Italian general population [47].
In males we did not find any significant association but only a
trend toward an increase in H5 frequency in AD males relative to
controls. It is to note that males are about one third of our total
AD sample, because they are less represented both among the
elderly [48] and in AD patients [49]. Thus, the negative
association between H5 sub-haplogroup and AD in men could
be explained by the smaller size of the AD male group. However, a
specific or more pronounced risk in women cannot at present be
excluded, given the growing evidence that components of the AD
phenotype differ significantly based on gender [50].
As for APOE, any association emerged between sub-haplogroup
mtDNA variation and APOE4 genotype, suggesting that they
likely exert an independent effect on AD. Previous results on this
topic are discordant, some Authors reporting a positive association
[43,31], while others no association [30,35] between haplogroups
and APOE4. Indeed, we found a strong association of APOE4
with age, this effect being particularly evident in females younger
than 76 years, i.e. the same age group where mtDNA sub-
haplogroup H5 appears to exert its major influence on AD.
In order to assess if the H5 background of the patients harboured
mutations responsible for the increased AD risk, we investigated the
complete mtDNA sequences of our H5 subjects. We did not find any
particular mutational pattern in the H5 patients (compared to
controls) except for a threefold increase of the H5 subgroup (H5a)
characterized by a transition at position 4336 (tRNA
Glngene) that has
been previously shown to be associated with AD [24,25], and a
sevenfold increase of the synonymous mutation at np 15833 which
defines the H5a1 sub-haplogroup. The latter finding is difficult to
explain unless that the high frequency of this C.T transition at np
15833 in AD patients is due to a mutational bias toward specific
codon usage at synonymous sites [16].
In addition sporadic mutations(showing up in one sampleonly)are
slightly more numerous in tRNA plus rRNA genes of AD samples
than in controls. This finding is also in keeping with growing
evidences showing that mutations in the protein synthesis machinery
of mitochondria may be frequent cause of human degenerative
diseases [42]. Thus our results confirm the relationship between
mtDNA sequence variation and AD and suggest that both ancient
polymorphisms defining sub-haplogroups and the accumulation of
sporadic mutations are most likely involved.
Further study will need to better focus on the genetic variation
falling in tRNA and rRNA genes, that is the mitochondrial
translation machinery. In fact a better characterization of the
molecular problems caused by these mutations in combination
with may be of help in characterizing different subgroups of
sporadic AD patients and help in their treatment.
Summarizing, the limitation of the present study is the lack of a
replication study in another population. Accordingly, we cannot
exclude population-specific effects. However, the large number of
patients and controls in our study allows us to largely exclude
possible false positive results. A replica of our study is quite
demanding, owing to difficulties in enrolling another comparable
large number of patients and of cognitively well assessed controls
either in the same geographic area or in other European countries.
The strengths are: (i) our study refers to a number of clinically well
assessed AD patients (936) and controls (776) which is quite
consistent; (ii) both AD patients and controls have been recruited
in a specific relatively large geographic area thus avoiding possible
bias related to a founder effect or population heterogeneity; (iii) the
control subjects have been tested for their cognitive capability; (iv)
we have identified for the first time a candidate risk sub-
haplogroup for AD which extends previous data regarding H-V
cluster on a more limited number of AD patients and controls in a
Polish population [31]; (v) we have provided 56 new mtDNA
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16243 D-loop (HVSI) T.C non coding 1 (2,6) 0 (0)
16256 D-loop (HVSI) C.T non coding 1 (2,6) 0 (0)
16291 D-loop (HVSI) C.T non coding 1 (2,6) 1 (5,5)
16294 D-loop (HVSI) C.T non coding 3 (7,9) 0 (0)
16304 D-loop (HVSI) T.C non coding 37 (97,4) 18 (100)
16311 D-loop (HVSI) T.C non coding 6 (15,8) 6 (33,3)
16312 D-loop (HVSI) A.G non coding 0 (0) 1 (5,5)
16320 D-loop (HVSI) C.T non coding 2 (5,3) 0 (0)
16335 D-loop (HVSI) A.G non coding 1 (2,6) 0 (0)
16352 D-loop (HVSI) T.C non coding 1 (2,6) 0 (0)
16357 D-loop (HVSI) T.C non coding 0 (0) 1 (5,5)
16362 D-loop (HVSI) T.C non coding 2 (5,3) 0 (0)
16391 D-loop G.A non coding 0 (0) 1 (5,5)
16497 D-loop A.G non coding 0 (0) 1 (5,5)
16519 D-loop T.C non coding 3 (7,9) 2 (11,1)
aNovel mutations are underlined and in italics.
bMutations resulting in an aminoacid change are in bold. NP (Not Polar), P (Polar), A (Acid).
doi:10.1371/journal.pone.0012037.t005
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not only suggest that sporadic mutations in mitochondrial tRNA
and rRNA genes could be involved in AD risk but also and more
in general represent a major contribution on mtDNA genetics
regarding this specific haplogroup in a Caucasian population; (vi)
we have pointed out the relationship between H5 mtDNA sub-
haplogroup and other well known risk factors for AD, such as
APOE4 genetic polymorphism and age. These data allowed us to
identify the subgroup of AD patients (younger than 75 years of
age; female sex) where H5 sub-haplogroup has a stronger effect.
Methods
DNA samples from 1712 (936 AD patients and 776 healthy
controls) unrelated central-northern Italian subjects were ana-
lyzed. The geographic origin and the number of samples for each
participating group were the following: Lombardy (405 patients;
192 controls), Veneto (248 patients; 414 controls), Tuscany (138
patients; 45 controls), Marche (145 patients; 125 controls). All
subjects were of Italian descent.
Patients were diagnosed by skilled evaluation units as suffering
from probable AD, according to NINCDS-ADRDA criteria [51]
and underwent a comprehensive geriatric assessment, including an
extended neuropsychological evaluation.
The control group was comparable for age, sex and ethnicity to
the patient group. A major characteristic of this control group is
that they were directly assessed by MMSE in order to exclude
subjects affected by cognitive deficiency. Written informed consent
was obtained from all control individuals and primary caregivers
on behalf of AD Patients. Written informed consent was obtained
from all control individuals and primary caregivers on behalf of
AD Patients. Each Institution which provided the DNA samples
received the approval from their own ethical committees. In
particular the Ethic committees of the: Italian National Research
Center for Ageing in Ancona, Department of Neurological and
Psychiatric Sciences of University of Florence, Regional Center for
Cerebral Ageing in Valdagno and the S. Giovanni di Dio-
Fatebenefratelli Center in Brescia have given their approval.
DNA was recovered from fresh blood by phenol-chloroform
standard procedures. MtDNA profiles in patients and controls
were determined by sequencing the entire mtDNA control region
for each subject from nucleotide position (np) 16024 to np 576.
This was followed by a hierarchical survey of haplogroup and sub-
haplogroup diagnostic markers in the coding region [20,47].
Figure 1. Phylogenetic network of the sub-haplogroup H5 complete sequences. Phylogenetic network based on the variation of 56 mtDNA
complete sequences from Italian subjects (GenBank accession numbers: GQ983055–GQ983110) relative to the revised Cambridge Reference Sequence (rCRS,
GenBank accession number: NC_012920). Numbers beside the nodes denote samples (Cases and Control subjects). Unless marked otherwise, the polymorphic
variants, shown on the lines connecting the nodes, are transitions. Letters following the polymorphic variants indicate transversions or insertions (i) or deletions
(d). Positions in bold are H5 specific mutations. We assigned a weight =10 to shared positions among all the samples and a weight =30 to the rare mutations
in the D-loop region, while we assigned a weight =70 to shared positions and a weight =90 to the rare variants in the coding region.
doi:10.1371/journal.pone.0012037.g001
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Patients and controls were stratified into two subgroups, according
to their APOE4 status: those carrying at least one APOE4 allele
(APOE4+) and non-APOE4 carriers (APOE4-).
Complete mtDNA sequences were obtained after treatment of
total DNA samples with REPLI-g Mitochondrial DNA kit (Qiagen,
Valencia, CA) for specific whole genome amplification of mtDNA,
followed by PCR amplification with MitoALL Resequencing kit
(Applera, Foster City, CA). The PCR products (5–10 ng) were
purifiedbyEXOSAPit(U.S.Biochemical,Cleveland,Ohio)andused
for direct sequencing with BigDye kit version 3.1 (Applera).
Electropherograms were inspected with SeqScape version 2.5
software (Applera). All the samples were aligned and compared with
the revised Cambridge Reference Sequence (rCRS) [40].
Reduced median network analyses, based on nucleotide variation
on the complete sequences, were carried out by Network 4.5.1.0
(http://fluxus-engineering.com) [53] with an e default value of zero.
Because of mutation rate heterogeneity in mtDNA there is not a
consensus on the weights to be assigned to the mutated nucleotide
positions. As reported in other studies [27,54] and after experimental
tests we choose to give different weights to nucleotide positions in the
D-loop and coding regions of our samples. After an initial run, we
summed the statistics (counts of each mutation) obtained for all
samples and used themto weight the characters from 10 to 90 with an
inverted linear relation against the number of occurrences in the
statistics.
Statistical Analysis
Mitochondrial sub-haplogroups, genotype frequencies and
gender were compared between AD patients and controls using
the x
2 or Fisher-exact test, while differences in age were
investigated through the non parametric Wilcoxon rank-sum test.
The mitochondrial sub-haplogroup variability envisages at least
40 subgroups, which have been further grouped into 19 subgroups
considering their frequencies and phylogenetic relationship.
The comparisons between each of the 19 mtDNA sub-
haplogroups in AD patients and controls have been computed
by applying both the Bonferroni’s adjustments and the Holm’s step
procedure. All analyses were performed separately for women and
men, as well as for the total group, and multivariate logistic
regression analysis using a stepwise procedure, adjusting for
significant interactions (considering a threshold level of 0.15), was
used to assess the relationship between independent variables
(mtDNA, APOE4 status, age and gender) and the outcome. Tests
for statistical significance were two-sided with =0.05; effect size
for the association was measured as odds ratio (OR) with 95%
confidence intervals (CI). SAS (9.1) statistical software from SAS
Institute, Cary (NC), was used for all statistical analyses.
Web Resources
Accession numbers and the URL for data presented herein are as
follows: GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (com-
plete H5 sequences [accession numbers GQ983055–GQ983110])
MITOMAP: A Human Mitochondrial Genome Database.
http://www.mitomap.org, 2009
mtDB: Human Mitochondrial Genome Database. www.genpat.
uu.se/mtDB
Network: Free Phylogenetic Network Software. http://www.
fluxus-engineering.com
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Table 6. Number of mutations found along the mtDNA
molecule regions in AD patients (N=936) vs controls
(N=776).
mtDNA region
N. mutations in
AD (N=534)
N. mutations in
CNT (N=261)
D-loop 235 115
ND1 4 2
ND2 44 24
COI 3 3
COII 5 3
ATPase8 1 1
ATPase6 41 24
COIII 1 0
ND3 6 2
ND4L 1 1
ND4 7 6
ND5 16 5
ND6 4 2
CytB 52 25
Total (genes) 185 98
Y1 0
R5 5
T2 0
C1 0
Q1 9 6
K3 0
F2 0
S1 0
S2 0 1
Total (tRNA) 34 12
12S 80 36
Total (rRNA) 80 36
doi:10.1371/journal.pone.0012037.t006
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